In the first clinical phase II trial using letrozole in epithelial ovarian cancer, it was observed that the probability of obtaining clinical benefit (either a response or stable disease) was associated with an increased level of ERα expression [85]. The gene discussed is ESR1; the disease is ovarian carcinoma.